Hematology and Blood Disorders

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Perspective - Hematology and Blood Disorders (2024) Volume 7, Issue 1

Multiple myeloma: Understanding the causes, symptoms, and treatment of a complex blood cancer

Abena Osei *

Department of Hematopathology, Tsinghua University, China

*Corresponding Author:
Abena Osei
Department of Hematopathology, Tsinghua University, China
E-mail: Osei99@tsinghua.edu.cn

Received: 28-Feb-2024, Manuscript No. AAHBD-24-135696; Editor assigned: 01-Mar-2024, PreQC No AAHBD-24-135696 (PQ) Reviewed:14-Mar-2024, QC No. AAHBD-24-135696Revised:20-Mar-2024, Manuscript No. AAHBD-24-1356962 (R); Published:27-Mar-2024, DOI:10.35841/aahbd-7.1.168

Citation: Osei A. Multiple myeloma: Understanding the causes, symptoms, and treatment of a complex blood cancer. Hematol Blood Disord. 2024;7(1):168

Visit for more related articles at Hematology and Blood Disorders

Introduction

Multiple myeloma is a hematologic malignancy characterized by the abnormal proliferation of plasma cells in the bone marrow. This complex disease affects the production of normal blood cells and can lead to a range of symptoms and complications. While multiple myeloma remains incurable, advancements in treatment options have significantly improved outcomes for patients in recent years. In this article, we'll delve into the intricacies of multiple myeloma, exploring its causes, symptoms, diagnosis, and treatment strategies [1].

Multiple myeloma arises from genetic mutations that cause plasma cells, a type of white blood cell responsible for producing antibodies, to become cancerous. These abnormal plasma cells, also known as myeloma cells, proliferate uncontrollably in the bone marrow, crowding out healthy blood cells and interfering with normal bone marrow function. As a result, patients with multiple myeloma may experience anemia, immunodeficiency, bone damage, and other complications [2].

The exact cause of multiple myeloma is unknown, but several factors may increase the risk of developing the disease. These risk factors include: Age: Multiple myeloma is more common in older adults, with the average age of diagnosis around 65-70 years old. Gender: Men are slightly more likely than women to develop multiple myeloma [3].

Race and Ethnicity: African Americans have a higher incidence of multiple myeloma compared to other racial and ethnic groups. Family History: Individuals with a family history of multiple myeloma or other plasma cell disorders may have an increased risk of developing the disease. Environmental Exposures: Exposure to certain environmental factors, such as radiation, certain chemicals, or toxins, may increase the risk of developing multiple myeloma [4].

Diagnosing multiple myeloma typically involves a combination of medical history, physical examination, laboratory tests, imaging studies, and bone marrow biopsy. Common diagnostic tests may include: Blood tests: Blood tests such as complete blood count (CBC), serum protein electrophoresis, and immunofixation electrophoresis can help detect abnormal levels of proteins and other markers associated with multiple myeloma. Urine tests: Urine tests may be performed to measure the levels of abnormal proteins, such as Bence Jones proteins, which are often elevated in patients with multiple myeloma [5].

Imaging studies: Imaging studies such as X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI), or positron emission tomography (PET) scans may be used to detect bone lesions, fractures, or other abnormalities associated with multiple myeloma. Bone marrow biopsy: A bone marrow biopsy involves the removal of a small sample of bone marrow tissue for examination under a microscope to confirm the presence of myeloma cells and assess disease severity [6].

Treatment for multiple myeloma aims to control the growth of cancer cells, relieve symptoms, and improve quality of life. Treatment strategies may vary depending on factors such as the patient's age, overall health, disease stage, and treatment goals. Common treatment options may include: Chemotherapy: Chemotherapy drugs, either alone or in combination with other medications, are often used to kill cancer cells and reduce tumor burden [7].

Immunomodulatory drugs (IMiDs): IMiDs such as thalidomide, lenalidomide, and pomalidomide are medications that help stimulate the immune system and inhibit the growth of myeloma cells. Proteasome inhibitors: Proteasome inhibitors such as bortezomib, carfilzomib, and ixazomib are drugs that block the action of proteasomes, cellular structures that break down proteins, thereby inducing apoptosis (programmed cell death) in myeloma cells [8].

Stem cell transplant: Autologous stem cell transplant may be considered for eligible patients, where high-dose chemotherapy is administered to destroy cancer cells followed by infusion of the patient's own stem cells to restore blood cell production [9].

Supportive care: Supportive care measures such as pain management, nutritional support, physical therapy, and psychosocial support are essential for managing symptoms, improving quality of life, and addressing the psychosocial impact of the disease [10].

Conclusion

Multiple myeloma is a complex and challenging blood cancer that requires a multidisciplinary approach to diagnosis, treatment, and supportive care. While multiple myeloma remains incurable, advances in treatment options have significantly improved outcomes for patients, leading to longer survival and better quality of life. By raising awareness, promoting early detection, and advancing research efforts, we can continue to make strides in the fight against multiple myeloma and improve outcomes for patients affected by this disease. Through collaboration among healthcare providers, researchers, advocacy organizations, and patients, we can work together to support individuals with multiple myeloma and ultimately strive for a future without this devastating cancer.

References

  1. Kelly M, Meenaghan T, Dowling M. Myeloma: Making sense of a complex blood cancer. British Journal of Nursing. 2010;19(22):1415-21.

    2. Indexed at, Google Scholar, Cross Ref

  2. Cuffe CH, Quirke MB, McCabe C. Patients' experiences of living with multiple myeloma. British Journal of Nursing. 2020;29(2):103-10.

    3. Indexed at, Google Scholar, Cross Ref

  3. Devenney B, Erickson C. Multiple myeloma: An overview. Clinl J Onco Nursing. 2004;8(4).

    4. Indexed at, Google Scholar

  4. Jagannath S. Pathophysiological underpinnings of multiple myeloma progression. J ManCare Phar2008 (7 Supp A):7-11.

    5. Indexed at, Google Scholar, Cross Ref

  5. Dvorak C. Common complaints, difficult diagnosis: Multiple myeloma. J the AmerAssociation of Nur Pract. 2006;18(5):190-4.

    6. Indexed at, Google Scholar, Cross Ref

  6. Dhakal B, Girnius S, Hari P. Recent advances in understanding multiple myeloma. F1000Research. 2016;5.

    7. Indexed at, Google Scholar, Cross Ref

  7. Brigle K, Rogers B. Pathobiology and diagnosis of multiple myeloma. In Seminars in oncology nursing 2017 (Vol. 33, No. 3, pp. 225-236). WB Saunders.

    8. Indexed at, Google Scholar, Cross Ref

  8. Rajkumar SV, Kumar S. Multiple myeloma: Diagnosis and treatment. In Mayo Clinic Proceedings 2016 (Vol. 91, No. 1, pp. 101-119). Elsevier.

    9. Indexed at, Google Scholar

  9. Seidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. The lancet oncology. 2003;4(9):557-64.

    10. Indexed at, Google Scholar, Cross Ref

  10. Furukawa Y, Kikuchi J. Molecular pathogenesis of multiple myeloma. Int Jof cli onco. 2015 ;20:413-22.

    11. Indexed at, Google Scholar, Cross Ref

Get the App